XML 67 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 28, 2016
USD ($)
Agreement
Dec. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Proceeds from the issuance of common stock   $ 250,500,000                 $ 250,478,974 $ 60,521,739   $ 56,585,035  
Revenues     $ 7,632,856 $ 27,375,778 $ 23,528,853 $ 29,454,579 $ 43,292,770 $ 42,696,636 $ 48,148,275 $ 34,657,896 $ 87,992,066 $ 168,795,577   $ 16,142,321  
Type of Revenue [Extensible List]     arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember   arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember  
Contract liabilities     $ 19,291,075       $ 77,769,629       $ 19,291,075 $ 77,769,629      
Collaboration and License agreements | Amgen Incorporated                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Agreement date Sep. 28, 2016                            
Number of agreements | Agreement 2                            
Cash received as due under collaboration agreement $ 35,000,000.0                            
Olpasiran Agreement | Amgen Incorporated                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Milestone payments 30,000,000.0                            
Olpasiran Agreement | Amgen Incorporated | Maximum                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Additional remaining development regulatory and sales milestones payments     400,000,000.0               400,000,000.0        
License Collaboration and Stock Purchase Agreement | Amgen Incorporated                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Proceeds from the issuance of common stock $ 21,500,000                            
Olpasiran and ARO-AMG1 Agreement | Amgen Incorporated                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Milestone payments                             $ 20,000,000
Revenues                     $ 20,100,000 $ 300,000 $ 16,100,000    
Type of Revenue [Extensible List]                     us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember    
Contract liabilities     0               $ 0        
Contract assets     $ 0               $ 0